口腔鳞状细胞癌免疫检查点的研究进展

doi:10.13701/j.cnki.kqyxyj.2019.12.001

口腔医学研究 ›› 2019, Vol. 35 ›› Issue (12): 1107-1110.DOI: 10.13701/j.cnki.kqyxyj.2019.12.001

• 特约述评 • 下一篇

口腔鳞状细胞癌免疫检查点的研究进展

孙志军^*, 武磊

武汉大学口腔医学院口腔基础医学省部共建国家重点实验室培育基地,口腔生物医学教育部重点实验室,武汉大学口腔医学院口腔颌面头颈肿瘤外科湖北武汉 430079

收稿日期:2019-10-30 出版日期:2019-12-28 发布日期:2019-12-23
通讯作者: 孙志军,E-mail:sunzj@whu.edu.cn
作者简介:孙志军,二级主任医师,珞珈特聘教授,博士生导师,口腔颌面头颈肿瘤外科副主任。发表第一作者或通讯作者SCI收录论文96篇。主持国家自然科学基金6项及湖北省自然科学基金杰出青年项目,参与国家重点研发计划1项。担任SCI杂志Oral Diseases编委,入选教育部新世纪优秀人才,获评中华口腔医学会邱蔚六口腔颌面外科发展基金曙光奖。主要科研方向为口腔鳞状细胞癌免疫逃逸机制及纳米药物。临床上主要擅长口腔颌面头颈肿瘤诊治、I¹²⁵组织间近距离放疗。作为第一完成人获得湖北省自然科学奖二等奖1项。
基金资助:
国家自然科学基金面上项目(编号:81672628、81874131)

Co-inhibitory Immune Checkpoints in Oral Squamous Cell Carcinoma

SUN Zhijun^*, WU Lei

The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei MOST) & Key Laboratory of Oral Biomedicine Ministry of Education; Department of Oral and Maxillofacial-Head and Neck Oncology, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, China.

Received:2019-10-30 Online:2019-12-28 Published:2019-12-23

摘要/Abstract

摘要： 以程序性细胞死亡1(programmed cell death 1, PD-1)免疫检查点阻断为代表的新型肿瘤免疫治疗,在临床上已经取得了突破性进展。然而,仍然有很多肿瘤患者对免疫检查点的治疗不响应。因此,进一步探讨免疫检查点的作用机制有助于口腔鳞状细胞癌的治疗。本文综述了部分共抑制免疫检查点信号的表达及其机制,并讨论将其作为口腔鳞状细胞癌的免疫治疗靶点的可能。

关键词: 口腔鳞状细胞癌, 免疫检查点, 免疫逃逸

Abstract: Clinical breakthroughs have been made in the treatment of cancer by immune checkpoint, especially by the antibody of PD-1.However, there are still many cancer patients who are not responsive to immune checkpoint blockade. Therefore, it is necessary to further study the mechanism of immune checkpoint, which could be exploited for oral squamous cell carcinoma (OSCC). In this review, we summarize the expression and the mechanism of partial co-inhibitory immune checkpoint molecules and discuss the possibility of targeting co-inhibitory immune checkpoints for the treatment of OSCC.

Key words: oral squamous cell carcinoma, immune checkpoint, immune escape

孙志军, 武磊. 口腔鳞状细胞癌免疫检查点的研究进展[J]. 口腔医学研究, 2019, 35(12): 1107-1110.

SUN Zhijun, WU Lei. Co-inhibitory Immune Checkpoints in Oral Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2019, 35(12): 1107-1110.

参考文献

[1] Ferris RL. Immunology and immunotherapy of head and neck cancer [J]. J Clin Oncol, 2015, 33(29): 3293-3304.
[2] Dogan V, Rieckmann T, Munscher A, et al. Current studies of immunotherapy in head and neck cancer [J]. Clin Otolaryngol, 2018, 43(1): 13-21.
[3] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy [J]. Nat Rev Cancer, 2012, 12(4): 252-264.
[4] Sharma P, Allison JP. The future of immune checkpoint therapy [J]. Science, 2015, 348(6230):56-61.
[5] Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial [J]. Lancet Oncol, 2016, 17(7): 956-965.
[6] Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck [J]. N Engl J Med, 2016, 375(19): 1856-1867.
[7] Yu GT, Bu LL, Huang CF, et al. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPalpha axis in HPV negative head and neck squamous cell carcinoma [J]. Oncotarget, 2015, 6(39): 42067-42080.
[8] Malm IJ, Bruno TC, Fu J, et al. Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma [J]. Head Neck, 2015, 37(8): 1088-1095.
[9] Jie HB, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients [J]. Br J Cancer, 2013, 109(10): 2629-2635.
[10] Adelstein D, Gillison ML, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 2.2017 [J]. J Natl Compr Canc Netw, 2017, 15(6): 761-770.
[11] Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition [J]. N Engl J Med, 2017, 377(25): 2500-2501.
[12] Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma [J]. Cancer Res, 2013, 73(6): 1733-1741.
[13] Kim HR, Ha SJ, Hong MH, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients [J]. Sci Rep, 2016, 6: 36956.
[14] Ock CY, Kim S, Keam B, et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma [J]. Oncotarget, 2016, 7(13): 15901-15914.
[15] Yu GT, Bu LL, Zhao YY, et al. CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma [J]. Oncoimmunology, 2016, 5(6): e1151594.
[16] Clavijo PE, Moore EC, Chen J, et al. Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells [J]. Oncotarget, 2017, 8:55804-55820.
[17] Strauss L, Bergmann C, Gooding W, et al. The frequency and suppressor function of CD4⁺CD25^highFoxp3⁺ T cells in the circulation of patients with squamous cell carcinoma of the head and neck [J]. Clin Cancer Res, 2007, 13(21): 6301-6311.
[18] Deng WW, Mao L, Yu GT, et al. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma [J]. Oncoimmunology, 2016, 5(11): e1239005.
[19] Xu F, Liu J, Liu D, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses [J]. Cancer Res, 2014, 74(13): 3418-3428.
[20] Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8⁺ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia [J]. Blood, 2011, 117(17): 4501-4510.
[21] Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints [J]. Nat Commun, 2016, 7: 10501.
[22] Liu JF, Ma S R, Mao L, et al. T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer [J]. Mol Oncol, 2017, 11(2): 235-247.
[23] Wu L, Deng WW, Yu GT, et al. B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma [J]. Cancer Immunol Immunother, 2016, 65(9): 1035-1045.
[24] Li J, Lee Y, Li Y, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8⁺ T cells [J]. Immunity, 2018, 48(4): 773-786.
[25] Lines JL, Pantazi E, Mak J, et al. VISTA is an immune checkpoint molecule for human T cells [J]. Cancer Res, 2014, 74(7): 1924-1932.
[26] Blando J, Sharma A, Higa MG, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer [J]. Proc Natl Acad Sci U S A, 2019, 116(5): 1692-1697.
[27] Gao J, Ward JF, Pettaway CA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer [J]. Nat Med, 2017, 23(5): 551-555.
[28] Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity [J]. Nat Immunol, 2018, 19(7): 723-732.
[29] Wu L, Mao L, Liu JF, et al. Blockade of TIGIT/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma [J]. Cancer Immunol Res, 2019, 7(10):1700-1713.

口腔鳞状细胞癌免疫检查点的研究进展

Co-inhibitory Immune Checkpoints in Oral Squamous Cell Carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	高安天, 林梓桐. 口腔鳞状细胞癌边界精准评价的光学成像研究进展[J]. 口腔医学研究, 2020, 36(5): 413-415.
[2]	杨凯成, 杨蕾, 赵建广, 罗风玉, 陈彦平, 崔子峰, 陈赫, 满莎莎. 口腔鳞状细胞癌患者外周血microRNA的表达及预后意义[J]. 口腔医学研究, 2020, 36(5): 428-432.
[3]	胡勤刚, 赵星星. 口腔鳞状细胞癌肿瘤相关成纤维细胞的研究进展[J]. 口腔医学研究, 2020, 36(4): 309-313.
[4]	郭俊峰, 张纲, 谭颖徽. CYP27B1在口腔鳞状细胞癌中的表达及其与预后的关系[J]. 口腔医学研究, 2020, 36(10): 930-933.
[5]	谢龙, 桑磊, 宋卓英, 江燕军. 唾液中微小RNA-375对口腔鳞状细胞癌的诊断价值及其对人口腔鳞状细胞癌细胞生物学功能的影响[J]. 口腔医学研究, 2019, 35(9): 883-888.
[6]	高旭,周阳,李琛,薛晓寒,魏秀峰. Eya4在口腔鳞状细胞癌中的表达及其意义[J]. 口腔医学研究, 2019, 35(6): 555-558.
[7]	周童,张桐菲,张泽兵,全海英. 甲基硒酸对口腔癌细胞增殖、迁移、凋亡和周期的作用研究[J]. 口腔医学研究, 2019, 35(6): 568-572.
[8]	熊璟,何元春,刘杰,张英,李永强,邱勇棋,庄瑞. 白藜芦醇通过调控雷帕霉素靶蛋白/M2型丙酮酸激酶轴抑制口腔鳞状细胞癌细胞的糖酵解作用[J]. 口腔医学研究, 2019, 35(6): 573-576.
[9]	陆展翼, 胡勤刚, 陈盛, 杨艳, 丁亮, 泥艳红. 口腔鳞状细胞癌组织TGF-β1表达和临床病理学参数对预后的影响[J]. 口腔医学研究, 2019, 35(5): 433-438.
[10]	刘艳玲, 赵曦, 余丽, 聂敏海. SOX-9在口腔鳞状细胞癌组织中的表达及其临床意义[J]. 口腔医学研究, 2019, 35(5): 439-442.
[11]	白真玉, 王铠, 刘德裕, 黄谢山. 长链非编码RNA FAL1在口腔鳞状细胞癌中的表达及其与预后的关系[J]. 口腔医学研究, 2019, 35(4): 360-363.
[12]	王晓乐, 贾荣. 口腔鳞状细胞癌患者年龄分布与肿瘤分子标记物的关系研究[J]. 口腔医学研究, 2019, 35(3): 238-241.
[13]	伍俊锋, 施斌, 曹裕杰, 陈法, 曹熔锴, 张诗蕾, 黄跃. 福建地区老年口腔鳞状细胞癌预后影响因素研究[J]. 口腔医学研究, 2019, 35(3): 242-245.
[14]	李勇伟,邱勋定,顾明,邓旎,谢莉莉. 同源形成素样蛋白2基因对口腔鳞状细胞癌侵袭、迁移及核因子-κB信号的影响[J]. 口腔医学研究, 2019, 35(2): 137-141.
[15]	戈春城, 汪羽, 何三纲, 徐佳, 王曦, 童国勇, 余周庆. DNA损伤诱导转录子4基因在口腔鳞状细胞癌中的表达及临床意义[J]. 口腔医学研究, 2019, 35(11): 1044-1047.